A venous-malignancy patient is still waiting for an injection after a botched operation at a hospital, but it doesn’t appear that his blood type was the problem.
A hospital in Missouri was caught up in the same controversy last year, after it was reported that the blood of a patient who had been treated at a different hospital had tested positive for a blood type that is more prevalent in the U.S.
Agency spokeswoman Jessica Kornstein said the agency was reviewing the case, and if that test showed it was the patient’s blood type, the agency would investigate the case further.
But the incident happened in 2014, when the agency wasn’t aware of the patient and didn’t test his blood.
The patient’s case is being investigated as a potential instance of misdiagnosis, which is the most common cause of hospital infections, according to the American Society of Critical Care Medicine.
The man in question is in stable condition and was discharged from the hospital on Thursday, Kornststein said.
He was hospitalized with the same blood type as another patient who died in a similar vein.
The CDC is currently conducting a study of the case to learn how many patients have had to wait more than a year for an initial dose of an antiretroviral drug.
If it proves to be an error, the drugmaker could be forced to pay the patient.
A recent case involving an infected vein was reported in the Washington Post, which prompted a number of media outlets to ask about the need for an industry-wide testing program.
In addition to the case in Missouri, there have been at least two other instances of patients waiting years or longer to receive an antiradiviral drug, according the Post.
In November, the company that makes Zantac, a drug used to treat toxoplasmosis, said it had to stop manufacturing the drug due to high demand.
That prompted the FDA to review all of the company’s sales and sales figures.
In February, a man in Florida was diagnosed with the deadly coronavirus and died from a blood infection, but the hospital in his hometown said it would not test his plasma because of the potential risk to patients.
The hospital had previously refused to test patients, citing a policy that doctors and nurses must be cleared for the testing.
The patient was treated with the drug, which has a half-life of about two weeks, and it took nearly three weeks to receive a positive result.
The FDA did not immediately respond to a request for comment on the Florida case.